Nickan Research Institute Immunopathologia Persa 2423-8015 5 2 2019 07 01 Lung cancer risk and the inhibitors of angiotensinconverting enzyme: A mini-review of recent evidence e16 e16 10.15171/ipp.2019.16 EN Masoumeh Asgharpour https://orcid.org/0000-0002-5504-4612 Mohammad Ebrahimi Kalan https://orcid.org/0000-0001-7709-5392 Seyed Hadi Mirhashemi Amirhesam Alirezaei https://orcid.org/0000-0001-9720-6723 Journal Article 10.15171/ipp.2019.16 2019 04 10 2019 06 20 Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.